This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-Hydroxytryptophan: Difference between revisions
>Graham m wiki ref formatting |
>Isaak Annotate SSRI interaction and SNRI interaction analogous to other articles (e.g. MDMA) |
||
| Line 88: | Line 88: | ||
Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | ||
*'''[[DangerousInteraction:: | *'''[[DangerousInteraction::SSRIs]]''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">{{cite journal | vauthors=((Ma, Z.)), ((Zhang, G.)), ((Jenney, C.)), ((Krishnamoorthy, S.)), ((Tao, R.)) | journal=European Journal of Pharmacology | title=Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats | volume=588 | issue=2–3 | pages=198–206 | date=7 July 2008 | issn=0014-2999 | doi=10.1016/j.ejphar.2008.04.004}}</ref><ref name="two">{{cite journal | vauthors=((Izumi, T.)), ((Iwamoto, N.)), ((Kitaichi, Y.)), ((Kato, A.)), ((Inoue, T.)), ((Koyama, T.)) | journal=European Journal of Pharmacology | title=Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats | volume=532 | issue=3 | pages=258–264 | date=27 February 2006 | issn=0014-2999 | doi=10.1016/j.ejphar.2005.12.075}}</ref> | ||
*'''[[ | *'''[[DangerousInteraction::SNRIs]]''' | ||
*'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | *'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | ||
*'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one" /><ref name="two" /> | *'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one" /><ref name="two" /> | ||